There are about 6,000 diseases identified as “rare” affecting approximately 300 million people worldwide.
We in the pharmaceutical industry have much to learn from these patients about the challenges they face to achieve their best health and well-being, especially from patients’ real voice.
Innovation starts from the passion to know.
I hope we take Rare Disease Day as an opportunity to learn about these patients’ journey to find the right diagnoses and care for themselves and their families.
We believe our pursuit of innovation and exploration of scientific discovery will deliver life-changing value for those living with rare diseases and bring smiles to our patients.
Masashi Miyamoto
Chief Executive Officer, Kyowa Kirin
More Kyowa Kirin "Patients" Stories
Our Stable Supply of High-quality Pharmaceuticals
Sustainability | September 20, 2023
Provide pharmaceuticals for unmet medical needs - A Conversation with Kyowa Kirin’s R&D Executives
Innovation | August 22, 2023
Ensure a Thriving Global Environment for Future Generations
Sustainability | July 28, 2023
“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅡ
People & Culture | June 9, 2023
How Kyowa Kirin Celebrated Rare Disease Day 2023 around The World
Patients | May 18, 2023
“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅠ
People & Culture | April 25, 2023
Kyowa Kirin CEO Miyamoto’s Message on Rare Disease Day
Patients | February 28, 2023
Promoting patient advocacy and nurturing patient-centric care: Interview with Kyowa Kirin North America
Patients | February 14, 2023
Celebrating another year of diverse initiatives around the world: RDD 2022 in EMEA
Patients | January 24, 2023
Celebrating another year of diverse initiatives around the world: RDD 2022 in North America
Patients | December 15, 2022
Celebrating another year of diverse initiatives around the world: RDD 2022 in Asia Pacific
Patients | November 21, 2022
Celebrating another year of diverse initiatives around the world: RDD 2022 in Japan
Patients | October 20, 2022
Providing high-quality pharmaceuticals to patients around the world
Sustainability | September 22, 2022
Striving to create life-changing “Only-one value” that brings smiles to patients
Innovation | July 25, 2022
Kyowa Kirin International: It's Time to Shine A Light on XLH
Patients | June 27, 2022
Kyowa Kirin CEO Miyamoto’s Message on Pride Month
People & Culture | June 9, 2022
Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA
People & Culture | January 20, 2022
Kyowa Kirin International: Around the world challenge
People & Culture | December 17, 2021
Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month
Patients | November 19, 2021
Kyowa Kirin's Effort to Realize a Sustainable Society
Sustainability | October 11, 2021
Our Financial Strategy for Creating Life-changing Value
Growth | September 9, 2021
Changes in society caused by COVID-19 and the impact on Kyowa Kirin
Growth | August 19, 2021
Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break
Sustainability | July 27, 2021
AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS
News Release | June 1, 2021
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting
News Release | May 20, 2021
White Paper on the unrecognized burden of XLH in adults in Europe
Patients | July 13, 2020
